173 related articles for article (PubMed ID: 15350372)
1. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Toyoshima M; Akahira J; Matsunaga G; Niikura H; Ito K; Yaegashi N; Tase T
Gynecol Oncol; 2004 Sep; 94(3):774-8. PubMed ID: 15350372
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
3. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Aghajanian C; Sill MW; Secord AA; Powell MA; Steinhoff M
Gynecol Oncol; 2012 Sep; 126(3):424-7. PubMed ID: 22634397
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
[TBL] [Abstract][Full Text] [Related]
5. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
Arimoto T; Nakagawa S; Yasugi T; Yoshikawa H; Kawana K; Yano T; Taketani Y
Gynecol Oncol; 2007 Jan; 104(1):32-5. PubMed ID: 16996113
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Curtin JP; Blessing JA; Soper JT; DeGeest K
Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
Tinker AV; Bhagat K; Swenerton KD; Hoskins PJ
Gynecol Oncol; 2005 Jul; 98(1):54-8. PubMed ID: 15904950
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
Hoskins PJ; Le N; Ellard S; Lee U; Martin LA; Swenerton KD; Tinker AV;
Gynecol Oncol; 2008 Jan; 108(1):58-62. PubMed ID: 17935761
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
[TBL] [Abstract][Full Text] [Related]
13. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
[TBL] [Abstract][Full Text] [Related]
14. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
